IMV Inc. (IMVIF)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Apr 24, 2026
0.00%
Market Cap 15.00
Revenue (ttm) n/a
Net Income (ttm) -37.99M
Shares Out 14.71M
EPS (ttm) -4.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,630
Average Volume 6,983
Open 0.0020
Previous Close 0.0000
Day's Range 0.0000 - 0.0020
52-Week Range n/a
Beta 4,526.03
RSI 47.58
Earnings Date n/a

About IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 63
Stock Exchange OTCMKTS
Ticker Symbol IMVIF
Full Company Profile

Financial Performance

News